{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:18:41Z","timestamp":1788931121481,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The classical natural history of chronic myeloid leukemia (CML) has been drastically modified by the introduction of tyrosine kinase inhibitor (TKI) therapies. TKI discontinuation is currently possible in patients in deep molecular responses, using strict recommendations of molecular follow-up due to risk of molecular relapse, especially during the first 6 months. We report here the case of a patient who voluntarily interrupted her TKI therapy. She remained in deep molecular remission (MR4) for 18 months followed by detection of a molecular relapse at +20 months. Despite this relapse, she declined therapy until the occurrence of the hematological relapse (+ 4 years and 10 months). Retrospective sequential transcriptome experiments and a single-cell transcriptome RNA-seq analysis were performed. They revealed a molecular network focusing on several genes involved in both activation and inhibition of NK-T cell activity. Interestingly, the single-cell transcriptome analysis showed the presence of cells expressing NKG7, a gene involved in granule exocytosis and highly involved in anti-tumor immunity. Single cells expressing as granzyme H, cathepsin-W, and granulysin were also identified. The study of this case suggests that CML was controlled for a long period of time, potentially <jats:italic>via<\/jats:italic> an immune surveillance phenomenon. The role of NKG7 expression in the occurrence of treatment-free remissions (TFR) should be evaluated in future studies.<\/jats:p>","DOI":"10.3389\/fonc.2023.1117781","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:17:24Z","timestamp":1678979844000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance"],"prefix":"10.3389","volume":"13","author":[{"given":"Jusuf","family":"Imeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Desterke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Chaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noufissa","family":"Oudrhiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Fund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Bennaceur-Griscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali G.","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":":917\u201327","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"285157","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"44053","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"365760","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"35293301","DOI":"10.18632\/oncotarget.9182","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation","volume":"7","author":"Chomel","year":"2016","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","first-page":"556572","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"396409","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe fran\u00e7ais des leuc\u00e9mies my\u00e9lo\u00efdes chroniques. discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"116676","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":":2859\u201368","DOI":"10.1186\/gb-2001-2-10-research0042","article-title":"Analysis of strain and regional variation in gene expression in mouse brain","volume":"2","author":"Pavlidis","year":"2001","journal-title":"Genome Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? the example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Sci (New York N.Y.)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"285968","DOI":"10.1021\/pr200210w","article-title":"Antileukemia activity of a natural killer cell line against human leukemias","volume":"4","author":"Yan","year":"1998","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"229096","DOI":"10.1172\/JCI488","article-title":"Cytotoxic T cell response against the chimeric P210 BCR-ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Yotnda","year":"1998","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.3484","article-title":"Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells","volume":"177","author":"Shimizu","year":"2006","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"187075","DOI":"10.1002\/eji.201142043","article-title":"Evidence for BCR-ABL-Dependent dysfunctions of INKT cells from chronic myeloid leukemia patients","volume":"42","author":"Rossignol","year":"2012","journal-title":"Eur J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100355","article-title":"In vivo potential of recombinant granulysin against human melanoma","volume":"27","author":"Al-Wasaby","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11519","DOI":"10.1016\/s0014-5793(03)00895-0","article-title":"Functional involvement of cathepsin W in the cytotoxic activity of NK-92 cells","volume":"552","author":"Wex","year":"2003","journal-title":"FEBS Lett"},{"key":"B20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.10.6404","article-title":"A novel serum protein that is selectively produced by cytotoxic lymphocytes","volume":"166","author":"Ogawa","year":"2001","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1016\/j.jim.2017.08.003","article-title":"Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21","volume":"450","author":"Streltsova","year":"2017","journal-title":"J Immunol Methods"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00879","article-title":"Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21","volume":"10","author":"Kweon","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jaci.2017.11.022","article-title":"S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate","volume":"141","author":"Drouillard","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"246981","DOI":"10.1084\/jem.20090525","article-title":"T-Bet-Dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow","volume":"206","author":"Jenne","year":"2009","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"175770","DOI":"10.1016\/j.celrep.2016.04.053","article-title":"The adhesion G protein-coupled receptor GPR56\/ADGRG1 is an inhibitory receptor on human NK cells","volume":"15","author":"Chang","year":"2016","journal-title":"Cell Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"110816","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"136877","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: The IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","first-page":"18292","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2018","journal-title":"Cancer Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"120518","DOI":"10.1038\/s41590-020-0758-6","article-title":"The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation","volume":"21","author":"Ng","year":"2020","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1117781\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:17:28Z","timestamp":1678979848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1117781\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":30,"alternative-id":["10.3389\/fonc.2023.1117781"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1117781","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"1117781"}}